GlobeNewswire Inc | Nov 8, 2021 04:05PM EST

November 08, 2021

FRAMINGHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (Definitive Healthcare) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2021.

Third Quarter 2021 Financial and Other Recent Highlights:

Financial Highlights:

-- Revenue was $43.1 million, an increase of 43% from $30.1 million in Q3 2020. -- GAAP Net loss was $(21.0) million, or 49% of revenue, compared to $10.0 million, or 33% of revenue in Q3 2020. -- Adjusted Net Income was $2.2 million, compared to $5.1 million in Q3 2020. -- Adjusted EBITDA was $14.4 million, or 33% of revenue, compared to $14.5 million, or 48% of revenue in Q3 2020. -- Cash flow from operations was ($0.9) million in the quarter or -2% of revenue. For the trailing twelve-month period, cash flow from operations was $29.7 million, or 19% of revenue. -- Unlevered free cash flow was $11.5 million in the quarter, or 27% of revenue. For the trailing twelve-month period, unlevered free cash flow was $59.1 million, or 38% of revenue.

I am extremely pleased with our performance in our first quarter as a public company, said Jason Krantz, founder and CEO of Definitive Healthcare. We saw strong revenue growth and continued to produce exceptional results. Our strength was broad-based across all of our segments, and we continue to innovate to build the next generation of healthcare commercial intelligence solutions. I want to thank all of our employees who have worked so diligently to help our customers create new paths to commercial success in the healthcare market.

Recent Business and Operating Highlights:

-- Definitive Healthcare successfully completed its initial public offering in September after selling 17,888,888 shares at a price of $27.00 per share, for aggregate gross proceeds of approximately $483 million. -- The company ended the quarter with 377 customers with $100,000 or greater in annual recurring revenue, a 49% increase from 252 in Q3 2020.

-- During the third quarter, the company brought on multiple new customers including:A large pharmaceutical technology company, who plans to use Definitive Healthcare commercial intelligence on executives, affiliations, procedure volumes, and doctors to accelerate its push into the hospital and IDN market for a new drug delivery implantable device.A market leader in the EHR market, who plans to use the Definitive Healthcare platform to identify which practices are using its competitions software, understand usage data including hospital bed counts and clinical metrics, and gain insight into the nature of the practices patients using claims data. One of the worlds leading venture capital firms, who will use Definitive Healthcare commercial intelligence to help them size and evaluate the market for potential investments in the healthcare space. One of the worlds largest global logistics providers, who subscribed to the Definitive Healthcare platform to help validate location and address data to ensure accurate package delivery to physicians and other healthcare providers. -- The company continues to deliver product innovations in response to customer demand. Some of these recent innovations include: An expansion of the PhysicianView product to include new intelligence around physician specialties, which allows clients to precisely target healthcare providers based on specific areas of focus. Users can now leverage claims-based specialty data to identify individual physicians, which means companies can sharpen their sales strategies with a better picture of their audience.An expansion of the HospitalView product to include new intelligence around organization charts. This new feature enables users to easily map out a hospitals different departments and subdepartments, understand the many layers of management, and identify the right people who may be searching for their product or service.In the Monocl product line, the company enhanced its ExpertInsight product by expanding the expert profiles with new indexed medical keywords to publications, clinical trials, grants and industry payments. These additions make it even easier for medical affairs professionals to identify the right clinical and scientific expert to assist in product development.

Business Outlook

Based on information as of November 8, 2021, the Company is issuing the following financial guidance.

Fourth Quarter 2021:

-- Revenue is expected to be in the range of $44 $45 million, a 32% increase year over year. -- Adjusted Operating Income is expected to be in the range of $11.5 $12.5 million. -- Adjusted EBITDA is expected to be in the range of $12.5 $13.5 million. -- Adjusted Net Income is expected to be $6 $7 million. -- Adjusted Net Income Per Diluted Share is expected to be $0.04 $0.05 on approximately 148.6 million weighted-average shares outstanding.

Full Year 2021:

-- Revenue is expected to be in the range of $164 $165 million. -- Adjusted Operating Income is expected to be in the range of $52 $53 million. -- Adjusted EBITDA is expected to be in the range of $55 $56 million. -- Adjusted Net Income is expected to be $13 $14 million. -- Adjusted Net Income Per Diluted Share is expected to be $0.08 $0.09 on approximately 148.5 million weighted-average shares outstanding.

Conference Call Information

Definitive Healthcare will host a conference call today, November 8, 2021, at 5:00 p.m. (Eastern Time) to discuss the Company's financial results and current business outlook. To access the call, dial (877) 407-3982 (domestic) or (201) 493-6780 (international). The conference ID number is 13723517. Shortly after the conclusion of the call, a replay of this conference call will be available through November 22, 2021 at (844) 512-2921 (domestic) or (412) 317-6671 (international). The replay passcode is 13723517. A live audio webcast of the event will be available on the Definitive Healthcares Investor Relations website at https://ir.definitivehc.com/.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities and people, so they can shape tomorrows healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more or sign up for a free trial at www.definitivehc.com.

Forward-Looking Statements

This press release may include forward-looking statements that reflect our current views with respect to future events and financial performance. Such statements are provided under the safe harbor protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by words or phrases written in the future tense and/or preceded by words such as likely, should, may, anticipates, intends, plans, seeks, believes, estimates, expects or similar words or variations thereof, or the negative thereof, references to future periods, or by the inclusion of forecasts or projections, but these terms are not the exclusive means of identifying such statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding our outlook, financial guidance, the market, industry and macroeconomic environment, our business, growth strategies, product development efforts and future expenses, and statements reflecting our expectations about our ability to execute on our strategic plans, achieve future growth and profitability and achieve our financial goals.

Forward-looking statements in this press release are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the following: an outbreak of disease, global or localized health pandemic or epidemic, or the fear of such an event (such as the COVID-19 global pandemic), including the global economic uncertainty and measures taken in response; the short- and long-term effects of the COVID-19 global pandemic, including the pace of recovery or any future resurgence; our inability to generate substantially all of our revenue and cash flows from sales of subscriptions to our platform and any decline in demand for our platform and the data we offer; the competitiveness of the market in which we operate and our ability to compete effectively; the failure to maintain and improve our platform, or develop new modules or insights for healthcare commercial intelligence; the inability to obtain and maintain accurate, comprehensive or reliable data, which could result in reduced demand for our platform; the risk that our recent growth rates may not be indicative of our future growth; the inability to achieve or sustain profitability in the future compared to historical levels as we increase investments in our business; the loss of our access to our data providers, which could negatively impact our platform; the failure to respond to advances in healthcare commercial intelligence; an inability to attract new customers and expand subscriptions of current customers; the risk of cyber-attacks and security vulnerabilities; and if our security measures are breached or unauthorized access to data is otherwise obtained, our platform may be perceived as not being secure, customers may reduce the use of or stop using our platform, and we may incur significant liabilities.

For additional discussion of factors that could impact our operational and financial results, refer to our final prospectus filed with the U.S. Securities and Exchange Commission (SEC) on September 16, 2021, our Quarterly Report on Form 10-Q for the three months ended September 30, 2021 that will be filed following this earnings release, and our subsequent SEC filings, which are or will be available on the Investor Relations page of our website at ir.definitivehc.com and on the SEC website at www.sec.gov.

Additional factors or events that could cause our actual performance to differ from these forward-looking statements may emerge from time to time, and it is not possible for us to predict all of them. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual financial condition, results of operations, future performance and business may vary in material respects from the performance projected in these forward-looking statements.

Any forward-looking statement made by us speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Website

Definitive Healthcare intends to use its website as a distribution channel of material company information. Financial and other important information regarding the Company is routinely posted on and accessible through the Companys website at [ https://www.definitivehc.com/]. Accordingly, you should monitor the investor relations portion of our website at [ https://ir.definitivehc.com/] in addition to following our press releases, SEC filings, and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the Email Alerts section of our investor relations page at [ https://ir.definitivehc.com/].

Basis of Presentation

A Reconciliation of GAAP to Non-GAAP results has been provided in the financial statement tables included at the end of this press release. An explanation of these measures is also included below under the heading Non-GAAP Financial Measures.

Non-GAAP Financial Measures

We have presented supplemental non-GAAP financial measures as part of this earnings release. We believe that these supplemental non-GAAP financial measures are useful to investors because they allow for an evaluation of the company with a focus on the performance of its core operations, including more meaningful comparisons of financial results to historical periods and to the financial results of peer and competitor companies.

We refer in this earnings release to Unlevered Free Cash Flow, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Operating Income and Adjusted Net Income as non-GAAP financial measures.These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles in the U.S., (GAAP). These are supplemental financial measures of our performance and should not be considered substitutes for net (loss) income, gross profit or any other measure derived in accordance with GAAP.

We define Unlevered Free Cash Flow as net cash provided from operating activities less purchases of property and equipment and other assets, plus cash interest expense, cash payments related to transaction related expenses and cash payments related to other non-recurring items. Unlevered Free Cash Flow does not represent residual cash flow available for discretionary expenditures since, among other things, we have mandatory debt service requirements.

We define EBITDA as earnings before debt-related costs, including interest expense, net and loss on extinguishment of debt and depreciation and amortization. Adjusted EBITDA is defined as EBITDA adjusted to exclude certain items of a significant or unusual nature, including equity-based compensation, transaction expenses and other non-recurring expenses. Adjusted EBITDA Margin is determined by calculating the percentage Adjusted EBITDA is of revenue. AdjustedEBITDA and Adjusted EBITDA Marginarekeymetricsusedbymanagementandourboardofdirectorstoassesstheprofitability of our operations.WebelievethatAdjustedEBITDA and Adjusted EBITDA Marginprovideusefulmeasurestoinvestorstoassessouroperatingperformancebecausethese metricseliminate non-recurring and unusual items and non-cash expenses, which we do not consider indicative of ongoing operational performance.Webelievethatthese metrics arehelpfultoinvestorsinmeasuringtheprofitabilityofouroperationsonaconsolidatedlevel.

We define Adjusted Gross Profit as revenue less cost of revenue (excluding acquisition-related depreciation and amortization and equity compensation costs) and Adjusted Gross Margin means Adjusted Gross Profit as a percentage of revenue. Adjusted Gross Profit differs from gross profit, in that gross profit includes acquisition-related depreciation and amortization expense and equity compensation costs. Adjusted Gross Profit and Adjusted Gross Margin are key metrics used by management and our board of directors to assess our operations. We exclude acquisition-related depreciation and amortization expenses as they have no direct correlation to the cost of operating our business on an ongoing basis. A small quantity of equity-based compensation is included in cost of revenue in accordance with GAAP but is excluded from our Adjusted Gross Profit calculations due to its non-cash nature.

We define Adjusted Operating Income as income (loss) from operations plus acquisition related amortization, equity-based compensation, transaction expenses and other non-recurring expenses.

We define Adjusted Net Income as Adjusted Operating Income less interest expense, net, foreign currency loss (gain) and including the incremental tax effects of adjustments to arrive at Adjusted Operating Income. We define Adjusted Net Income Per Share as Adjusted Net Income divided by diluted weighted average outstanding shares.

Our use of these non-GAAP terms may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies and are not measures of performance calculated in accordance with GAAP. Our presentation of these non-GAAP financial measures are intended as supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. These non-GAAP financial measuresshould not be considered as alternatives to (loss) income from operations, net (loss) income, gross profit, earnings per share or any other performance measures derived in accordance with GAAP, or as measures of operating cash flows or liquidity.

We do not provide a quantitative reconciliation of the forward-looking non-GAAP financial measures included in this press release to the most directly comparable GAAP measures due to the high variability and difficulty to predict certain items excluded from these non-GAAP financial measures; in particular, the effects of stock-based compensation expense, taxes and amounts under the exchange tax receivable agreement, deferred tax assets and deferred tax liabilities, and restructuring and transaction expenses. We expect the variability of these excluded items may have a significant, and potentially unpredictable, impact on our future GAAP financial results.

In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in these presentations.

Investor Contact:Brian DenyeauICR for Definitive Healthcarebrian.denyeau@icrinc.com646-277-1251

Media Contact:Danielle Johnsdjohns@definitivehc.com





Definitive Healthcare Corp.Condensed Consolidated Balance Sheets(amounts in thousands, except number of shares)

September30, December31, 2021 2020Assets (unaudited) Current assets: Cash and cash equivalents 189,752 24,774 Accounts receivable, net 27,886 33,108 Prepaid expenses and other current assets 3,642 3,016 Current portion of deferred contract costs 5,359 2,947 Total current assets 226,639 63,845 Property and equipment, net 4,697 3,248 Other assets 747 472 Deferred contract costs, net of current portion 9,388 5,952 Deferred tax asset 161 161 Intangible assets, net 366,723 410,237 Goodwill 1,261,444 1,261,444 Total assets $ 1,869,799 $ 1,745,359 Liabilities and Equity Current liabilities: Accounts payable 7,055 5,662 Accrued expenses and other current liabilities 19,296 17,321 Current portion of deferred revenue 69,811 61,060 Current portion of term loan 6,875 4,680 Total current liabilities 103,037 88,723 Long term liabilities: Deferred revenue 368 140 Tax receivable agreements liability 146,106 ? Term loan, net of current portion 265,388 457,197 Deferred tax liabilities 71,341 ? Other long-term liabilities 475 3,736 Total liabilities 586,715 549,796 Commitments and Contingencies Equity: Members' equity ? 1,195,694 ClassA Common Stock, par value $0.001,600,000,000 shares authorized, 88,263,333 88 ? shares issued and outstanding at September30,2021ClassB Common Stock, no par value, 65,000,000shares authorized, 60,020,525 shares issued and ? ? 57,220,661 outstanding at September30, 2021Additional paid-in capital 700,773 ? Accumulated other comprehensive income (loss) 24 (131 )Accumulated deficit (7,978 ) ? Noncontrolling interests 590,177 ? Total equity 1,283,084 1,195,563 Total liabilities and equity $ 1,869,799 $ 1,745,359



Definitive Healthcare Corp. Condensed Consolidated Statements of Operations (amounts in thousands, except share amounts and per share data; unaudited) Three Months Ended Nine Months Ended September30, September30, 2021 2020 2021 2020 Revenue $ 43,084 $ 30,073 $ 119,841 $ 84,659 Cost of revenue: Cost of revenueexclusive of 5,129 2,619 13,895 7,876 amortizationshown below ^(1)Amortization 5,356 4,794 15,896 14,278 Gross profit 32,599 22,660 90,050 62,505 Operating expenses:Sales and 14,376 8,292 39,003 23,542 marketing ^(1)Product 4,746 2,618 12,817 7,566 development ^(1)General andadministrative ^ 7,880 2,538 18,891 8,105 (1)Depreciation and 9,760 10,112 28,814 30,037 amortizationTransaction (137 ) 40 3,332 748 expensesTotal operating 36,625 23,600 102,857 69,998 expenses Loss from (4,026 ) (940 ) (12,807 ) (7,493 ) operationsOther expense, net:Foreign currencytransaction 119 - 143 - (loss) gainInterest (7,186 ) (9,022 ) (23,956 ) (27,802 ) expense, netLoss onextinguishment (9,873 ) - (9,873 ) - of debtTotal other (16,940 ) (9,022 ) (33,686 ) (27,802 ) expense, net Net loss (20,966 ) (9,962 ) (46,493 ) (35,295 ) Less: Net lossattributable toDefinitive OpCo (7,816 ) (9,962 ) (33,343 ) (35,295 ) prior to theReorganizationTransactionsLess: Net lossattributable to (5,172 ) - (5,172 ) - noncontrollinginterests Net lossattributable to $ (7,978 ) $ ? $ (7,978 ) $ ? DefinitiveHealthcare Corp.Net loss pershare of Class A Common Stock:Basic and $ (0.09 ) N/A $ (0.09 ) N/A dilutedWeighted averagecommon stock outstanding:Basic and 88,263,333 N/A 88,263,333 N/A diluted ^(1) Amountsincludeequity-based compensationexpense asfollows: Three Months Ended Nine Months Ended September30, September30, 2021 2020 2021 2020 Cost of revenue $ 48 $ 16 $ 79 $ 46 Sales and 326 132 567 380 marketingProduct 187 93 341 267 developmentGeneral and 1,756 217 3,351 637 administrativeTotalequity-based $ 2,317 $ 458 $ 4,338 $ 1,330 compensationexpense

Definitive Healthcare Corp. Condensed Consolidated Statements of Cash Flows (amounts in thousands; unaudited) Three Months Ended Nine Months Ended September30, September30, 2021 2020 2021 2020 Cash flows provided by operating activities:Net loss $ (20,966 ) $ (9,962 ) $ (46,493 ) (35,295 )Adjustments toreconcile net loss tonet cash (used in) provided by operatingactivities:Depreciation and 452 301 1,193 817 amortizationAmortization of 14,664 14,605 43,517 43,498 intangible assetsAmortization ofdeferred contract 1,293 449 3,195 1,038 costsEquity-based 2,317 458 4,338 1,330 compensationNoncash paid in kind ? 3,017 ? 7,371 interest expenseAmortization of debt 475 514 1,522 1,541 issuance costsProvision for doubtful 181 204 76 579 accounts receivableLoss on extinguishmentof debt (non-cash 9,843 ? 9,843 ? portion)Changes in fair valueof contingent (212 ) ? 3,169 ? considerationChanges in operatingassets and liabilities:Accounts receivable (5,297 ) (1,130 ) 5,179 3,936 Prepaid expenses and 53 (102 ) (561 ) (39 )other current assetsDeferred contract (3,001 ) (1,769 ) (9,043 ) (4,341 )costsAccounts payable,accrued expenses and (1,846 ) (3,344 ) (3,965 ) (7,283 )other currentliabilitiesDeferred revenue 1,096 (2,446 ) 9,023 1,392 Net cash (used in)provided by operating (948 ) 795 20,993 14,544 activitiesCash flows used in investing activities:Purchases of property,equipment, and other (440 ) (166 ) (5,662 ) (1,061 )assetsCash paid foracquisitions, net of ? (6,935 ) ? (6,935 )cash acquiredNet cash used in (440 ) (7,101 ) (5,662 ) (7,996 )investing activitiesCash flows provided by(used in) financing activities:Proceeds from term 275,000 ? 275,000 ? loanRepayments of term (470,402 ) (1,125 ) (472,742 ) (3,375 )loansProceeds fromrevolving credit ? ? ? 25,000 facilityPayment of contingent ? ? (1,500 ) ? considerationPayment of debt (3,511 ) ? (3,511 ) ? issuance costsProceeds from equityoffering, net of 452,812 ? 452,812 ? underwriting discountsRepurchase ofoutstanding equity/ (92,812 ) ? (92,812 ) Definitive OpCo unitsPayments of IPO (4,519 ) ? (5,913 ) ? issuance costsMember contributions ? ? 5,500 ? Member distributions (3,811 ) (2,061 ) (7,139 ) (2,109 )Net cash provided by(used in) financing 152,757 (3,186 ) 149,695 19,516 activitiesNet increase(decrease) in cash and 151,369 (9,492 ) 165,026 26,064 cash equivalentsEffect of exchangerate changes on cash (55 ) ? (48 ) ? and cash equivalentsCash and cashequivalents, beginning 38,438 44,174 24,774 8,618 of periodCash and cashequivalents, end of $ 189,752 $ 34,682 $ 189,752 $ 34,682 periodSupplemental cash flow disclosures:Cash paid for interest $ 11,615 $ 9,157 $ 27,587 $ 23,043 Cash paid for income ? ? 13 ? taxesSupplementaldisclosure of non-cash investing activities:Net increase(decrease) in accruedcapital expenditures, 369 ? (3,020 ) ? including purchases ofdataSupplementaldisclosure of non-cash financing activities:Increase in unpaid $ 3,055 $ ? $ 5,481 $ ? public offering costs

Definitive Healthcare Corp. Reconciliations of Non-GAAP Financial Measures to Closest GAAP Equivalent Reconciliation of GAAP Operating Cash Flow to Unlevered Free Cash Flow (in thousands; unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cash flow from $ (948 ) $ 795 $ 20,993 $ 14,544 operationsPurchases ofproperty and (440 ) (166 ) (5,662 ) (1,061 ) equipment and otherassetsInterest paid in 11,615 9,157 27,587 23,043 cashTransactionexpenses paid in 75 40 163 748 cash^ (a)Other non-recurring 1,149 37 3,313 1,804 items ^(b)Unlevered Free Cash $ 11,451 $ 9,863 $ 46,394 $ 39,078 Flow (a) Transaction expenses paid in cash primarily represent legal, accounting andconsulting expenses related to our acquisitions. (b) Non-recurring items represent expenses that are typically one-time or non-operational in nature. Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income and GAAP OperatingIncome to Adjusted Operating Income (in thousands, except per share amounts; unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net loss $ (20,966 ) $ (9,962 ) $ (46,493 ) $ (35,295 ) Add: Interest 7,186 9,022 23,956 27,802 expense, netAdd: Loss fromextinguishment from 9,873 - 9,873 - debtAdd: Foreigncurrency loss (119 ) - (143 ) - (gain)Loss from $ (4,026 ) $ (940 ) $ (12,807 ) $ (7,493 ) operationsAdd: Amortizationof acquired 5,096 4,759 15,125 14,175 technologyAdd: Amortizationof other acquired 9,308 9,811 27,621 29,220 intangiblesAdd: Equity-based 2,317 458 4,338 1,330 compensationAdd: Transaction (137 ) 40 3,332 748 expensesAdd: Other 1,149 37 3,313 1,804 non-recurring itemsAdjusted Operating $ 13,707 $ 14,165 $ 40,922 $ 39,784 IncomeLess: Interest (7,186 ) (9,022 ) (23,956 ) (27,802 ) expense, netLess: Foreigncurrency (loss) 119 - 143 - gainLess: Tax impactsof adjustments to (4,472 ) - (10,304 ) - net income (loss)Adjusted Net Income $ 2,168 $ 5,143 $ 6,805 $ 11,982 Shares for Adjusted Net Income Per 148,298,331 148,298,331 Share ^(a)

Adjusted Net Income $ 0.01 $ 0.05 Per Share (a) Diluted Adjusted Net Income Per Share is computed by giving effect toall potential weighted average Class A common stock and any securities that areconvertible into Class A common stock, including Definitive OpCo units andrestricted stock units. The dilutive effect of outstanding awards and convertible securities is reflected in diluted earnings per share byapplication of the treasury stock method assuming proceeds from unrecognizedcompensation as required by GAAP. Fully diluted shares are 149,745,883 as ofSeptember 30, 2021. Reconciliation of Adjusted EBITDA to GAAP Net (Loss) Income (in thousands; unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net loss $ (20,966 ) $ (9,962 ) $ (46,493 ) $ (35,295 ) Interest expense, 7,186 9,022 23,956 27,802 netLoss fromextinguishment of 9,873 - 9,873 - debtDepreciation & 15,116 14,906 44,710 44,315 amortizationEBITDA $ 11,209 $ 13,966 $ 32,046 $ 36,822 Other (income) (119 ) - (143 ) - expense, net ^(a)Equity-based 2,317 458 4,338 1,330 compensation ^(b)Transaction (137 ) 40 3,332 748 expenses ^(c )Other non-recurring 1,149 37 3,313 1,804 items ^(d)Adjusted EBITDA $ 14,419 $ 14,501 $ 42,886 $ 40,704 Revenue $ 43,084 $ 30,073 $ 119,841 $ 84,659 Adjusted EBITDA 33 % 48 % 36 % 48 % margin (a) Primarily represents foreign exchange remeasurement gains and losses.(b) Equity-based compensation represents non-cash compensation expenserecognized in association with equity awards made to employees and directors.(c) Transaction expenses primarily represent legal, accounting and consulting expenses and fair value adjustments for contingent consideration related to ouracquisitions.(d) Non-recurring items represent expenses that are typically one-time ornon-operational in nature. Reconciliation of Adjusted Gross Profit to GAAP Gross Profit(in thousands; unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Reported gross $ 32,599 $ 22,660 $ 90,050 $ 62,505 profitAmortization ofintangible assetsresulting from 5,096 4,759 15,125 14,175 acquisition-relatedpurchase accountingadjustments ^(a)Equity compensation 48 16 79 46 costsAdjusted Gross $ 37,743 $ 27,435 $ 105,254 $ 76,726 ProfitRevenue $ 43,084 $ 30,073 $ 119,841 $ 84,659 Adjusted Gross 88 % 91 % 88 % 91 % Margin (a) Amortization of intangible assets resulting from purchase accountingadjustments represents non-cash amortization of acquired intangibles, primarily resulting from the Advent acquisition.